B
reast cancer is one of the most common malignancies that occur in women in the United States, accounting for one in four female cancers. Breast cancer develops as a result of abnormal proliferation of cells in the mammary gland. Normal growth of mammary epithelial cells is modulated by circulating levels of estrogen, a female hormone produced by the ovaries. The activity of estrogen is mediated by the estrogen receptors (ERs), ER␣ and ER␤. These two isoforms of ER display considerable homology in their DNA binding domains and COOH-terminal domains but are highly variable in their NH 2 -terminal trans-activation function-1 domains (3, 4) . Both ER␣ and ER␤ bind to the active form of estrogen, 17␤-estradiol (E 2 ), with similar affinities. They function as ligand-gated transcription factors that control the expression of genes necessary for growth, development, and homeostasis. However, the two forms of ER play very different roles in breast cancer. ER␣ has long been known as a crucial regulator of growth and development of the mammary gland and also as a key prognostic marker for breast cancer development. Although ER␤ has been reported to be present in breast cancer cells, less is known about its role in breast cancer development.
Breast cancer can be classified as either ER positive or ER negative, depending on the presence or absence of ER␣. Development of ER-positive breast cancer is controlled by the activity of the ERs and the circulating levels of 17␤-E 2 . The role of ER␣ in hormone-refractory breast tumorigenesis and the underlying mechanism of this role are unclear. Endocrine disruptors, including heavy metals such as cadmium (Cd), may be involved in ER␣-mediated modulation of hormone-refractory breast tumorigenesis (1, 2, (5) (6) (7) . Although Cd exposure has been associated with the development of breast cancer, the nature of this relationship remains unclear (1, 2, (5) (6) (7) .
Cd is derived from various industrial sources, including present and former mining activities and the production of alloys, batteries, fertilizers, pigments, and combustion byproducts. Human exposure results from consumption of contaminated water and food or inhalation of cigarette smoke and metal smoldering fumes. Cd is part of the family of heavy metals that exists as a natural component of the Earth's crust. Thus, it is present in varying concentrations in all ecosystems. In general, heavy metals cannot be degraded and often accumulate in biota, water, and soil. Because heavy metals form complexes with organic compounds, high levels of heavy metals have been shown to be dangerous to all living organisms. Heavy metals often alter the activity of biological molecules and hinder their ability to function properly by binding to nitrogen-, oxygen-, or sulfur-containing groups, ultimately interfering with cellular processes. Common toxicities affecting higher eukaryotic cells include impaired mitochondrial function, enhanced levels of free radicals, and DNA damage, all of which can result in death or malignant transformation. Exposure to elevated levels of Cd and other heavy metals has been associated with an increased incidence of breast cancer development (6, 8) . In particular, Cd, nickel, mercury, and selenium have been shown to have estrogenic effects and are collectively referred to as metalloestrogens.
Recent studies have suggested that metalloestrogens may function as endocrine disruptors, perturbing the normal hormonal cycle and altering the development of the mammary gland, resulting in neoplastic growth (1, 2) . Cd is the best characterized of the metalloestrogens. Specifically, animal studies have shown that Cd exposure can increase uterine weight and density of the mammary gland, as well as induce changes in the lining of the uterus, which are all early signs of tumorigenesis (2) . Cd can mimic the action of estrogen in breast cancer cells by binding to the ER and mediating receptor activation in vitro (1, 6, 7) . Although Cd is known to bind to ER␣, its role in ER␣-mediated gene expression and breast cancer cell growth remains unclear.
This study aims to further investigate the mechanism of Cd-induced breast cancer cell proliferation and gene expression and to determine the role of ER␣ in this process. We provide several lines of evidence that suggest that the effects of Cd on breast cancer cell growth and gene expression are dependent on ER␣. Our results show that Cd promotes the nuclear localization of ER␣ and enhances the binding of ER␣ to the promoters of cyclin D1 (CycD1) and c-myc. We also demonstrate that Cd potentiates the interaction between ER␣ and c-Jun, a member of the activating protein (AP)-1 family of transcription factors. Taken together, our results suggest that Cd promotes the ER␣/c-Jun interaction and increases recruitment of the ER␣/c-Jun complex to promoter regions, thereby directly regulating the expression of Cd-inducible genes.
Results
To determine whether Cd has an effect on ER-positive breast cancer cell growth, three ER-positive breast cancer cell lines, MCF-7, T-47D, and ZR-75-1, were plated in six-well plates in hormone-deprived media and treated with 10 Ϫ6 M cadmium chloride (CdCl 2 ), 10
or were mock treated with PBS (Fig. 1A ). For each cell type, the optimal Cd concentration was determined using a titration assay in which cells were plated in a 96-well plate and treated with varying concentrations of CdCl 2 , ranging from 10 Ϫ12 M to 10 Ϫ5 M (data not shown). The results shown in Fig. 1A indicate that Cd enhanced the growth rate of all three ER-positive breast cancer cell lines (MCF-7, T-47D, and ZR-75-1), relative to the mock control. As expected, cells treated with E 2 displayed a significant increase in cell growth, compared with mocktreated cells. These results were further confirmed by indirect cell proliferation assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (data not shown). Although Cd affects cell proliferation to a lesser degree than E 2 , our results do indicate that Cd stimulates ER-positive breast cancer cell growth.
To dissect the molecular mechanism of Cd's action on breast cancer cell growth, we examined whether Cd was able to induce ER target gene expression. MCF-7 cells were hormone deprived and treated with 10 Ϫ6 M CdCl 2 .
Total RNA was isolated, and the expression levels of several ER target genes were analyzed by semiquantitative RT-PCR (Fig. 1B) . Cd-treated MCF-7 cells expressed higher levels of CycD1 and c-myc as early as 24 h after exposure, whereas cathepsin D (CTD) displayed a more delayed response (48 h). These three genes have been shown to be important in the development and progression of breast cancer (11) (12) (13) (14) (15) (16) (17) . Cd exposure had no detectable effect on the expression level of pS2, an estrogenresponsive gene that is commonly used as a prognostic marker of breast cancer (18, 19) . We also examined the expression of p21, a cell cycle inhibitor that has been shown to be regulated by ER␣ (12, 20) and found that expression of p21 was decreased by Cd exposure. Consistent with its inhibitory role in the cell cycle, reduction of p21 levels may serve as an alternative mechanism by which Cd promotes cell proliferation. Alternatively, re-duced p21 levels may work in conjunction with elevated levels of CycD1 and c-myc to promote cell growth. The observation that Cd stimulated breast cancer cell proliferation led us to expand our analysis to other genes directly involved in cell cycle regulation. To this end, we included cyclins and cyclin-dependent kinases (CDKs) in our analysis. Our results show that expression of cyclin E1 (CycE), cdk2, and cdk4 increased after Cd treatment, whereas the other cyclins and CDKs showed no significant changes in their expression levels after treatment (Fig. 1B) .
Western blot analysis was used to determine whether the protein levels of these genes were affected by Cd treatment (Fig. 1C) To determine whether Cd-induced breast cancer cell proliferation is dependent on ER␣, we silenced ER␣ expression using siRNA, and cell growth was analyzed 2, 3, and 4 d after treatment ( Fig. 2C and data not shown). Cells transfected with siRNA directed against ER␣ (Ri-ER␣) did not grow in response to the Cd or estrogen (E 2 ), whereas cells transfected with a scrambled siRNA control (Ri-control) continued to be stimulated by Cd and estrogen treament (Fig. 2C) . Consistent with the growth results, Ri-ER␣ also diminished the effects of Cd-induced CycD1 and c-myc expression at the mRNA level (Fig. 2D) .
Next, we examined the role of ER␤ in Cd-induced cell growth using small interfering RNA (siRNA) to deplete endogenous ER␤ expression. Cell growth was monitored 2, 3, and 4 d after treatment (Fig. 2E and data not shown). Interestingly, cells transfected with Ri-ER␤ displayed an increase in cell proliferation under all three conditions (mock, Cd, and estrogen treated). Furthermore, our results also suggest that ER␤ depletion has no effect on Cd or estrogen response (Fig. 2E ). Western blot analysis was used to monitor the ER␤ expression. Cells transfected with Ri-ER␤ expressed significantly lower levels of ER␤ 48 h after treatment; however, depletion of ER␤ did not have any significant effects on the expression of CycD1 and c-myc at the protein level (Fig. 2F) .
To further assess the role of ER␣ in Cd-induced cell proliferation, we analyzed the effects of Cd on the growth induced breast cancer cell growth is dependent on ER␣, and not ER␤.
Given that Cd-induced cell proliferation and gene expression may be dependent on ER␣, we postulated that Cd may stimulate ER␣ nuclear localization. To determine whether Cd promotes the nuclear translocation of ER␣, MCF-7 cells were hormone deprived for 2 d and treated with 10 Ϫ6 M CdCl 2 (Cd) or 10 Ϫ8 M E 2 , or were mock treated for 0.5, 2, and 4 h (Fig. 3 ). Cells were harvested by fixation in formaldehyde, and ER␣ was examined by immunofluorescence and counterstained with 4Ј,6-diamidino-2-phenylindole (DAPI) to identify nuclei. ER␣ proteins are normally localized in both the cytoplasm and nucleus; however, when cells are hormone deprived, a majority of the ER␣ proteins are found in the cytoplasm (Fig. 3) . As shown in Fig. 3 , Cd promotes the nuclear translocation of ER␣, starting at 1 h and peaking at 4 h after treatment (Fig. 3) . As expected, E 2 treatment also stimulates the translocation of ER␣ to the nucleus. However, the translocation effect was much quicker under estrogen condition, with maximum translocation observed after 30 min of treatment (Fig. 3) . These data suggest that Cd acts similarly to estrogen in promoting ER␣ nuclear localization. Once inside the nucleus, the Cd-ER␣ complex may regulate the expression of Cd-induced genes (i.e. CycD1 and c-myc).
Because Cd promotes translocation of ER␣ to the nucleus, we questioned whether ER␣ is required for the expression of Cd-induced genes. To address this issue, we analyzed the trans-activation of CycD1 and c-myc promoters in the presence and absence of ER␣. We performed a reporter gene assay by transfecting MCF-7 cells with a plasmid containing a luciferase gene directly linked to either the CycD1 (1.7 kb) or the c-myc (2.1 kb) promoter sequences along with siRNA directed against ER␣ or a scramble siRNA control. Cells transfected with an empty vector served as a negative control. After transfection, cells were treated with either Cd, propyl pyrazole triol (PPT), a highly selective ER␣ agonist, or Cd in the presence of PPT. Cells mock treated with PBS served as the negative control. Results in Fig. 4 , A and B, demonstrate that Cd treatment modestly increases the transcriptional activity at both the CycD1 and c-myc promoters by 3-and 4-fold, respectively, in cells transfected with the Ri-Control. As expected, PPT also trans-activated the two ER␣-regulated promoters (4.5-fold for CycD1 and 5.3-fold for c-myc). Interestingly, the combination of Cd and PPT only resulted in a slightly higher trans-activation, suggesting the absence of synergistic effects between the two agonists ( nists likely have additive rather than synergistic effects (Supplemental Fig. 2 ). On the other hand, cells transfected Ri-ER␣ displayed a significant decrease in the trans-activation at both the CycD1 and c-myc promoters, suggesting that Cd induction of CycD1 and c-myc transcription is dependent on the presence of ER␣. This result was also confirmed by transfecting cells with the CycD1 and c-myc luciferase reporter construct, followed by ICI treatment. Similar to Ri-ER␣, cells treated with ICI expressed significantly less ER␣ (Fig. 2B) , and the transactivation of both CycD1 and c-myc promoters were decreased by ICI even in the presence of Cd and 17␤-E 2 (Supplemental Fig. 3) .
Because Cd increased the transcriptional activity of both CycD1 and c-myc promoters, we questioned whether Cd exposure promotes ER␣ recruitment to target gene promoters using a chromatin immunoprecipitation (ChIP) assay. Results in Fig. 4 , C and D, show an increase in ER␣ occupancy at the proximal promoter regions of both CycD1 and c-myc upon Cd treatment. However, promoter sequences of genes that are not regulated by ER␣, such as the U6 RNA promoter, were not detected in the ER␣ immunoprecipitates. These results establish a direct link between ER␣ and Cd-induced breast carcinogenesis.
Because ER␣ is normally recruited to the CycD1 and c-myc promoters via the AP-1 family of transcription factors, we analyzed whether Cd treatment promotes ER␣/ AP-1 interaction in ER␣-positive breast cancer cells by coimmunoprecipitation. MCF-7 cells were treated with 10 Ϫ6 M CdCl 2 , cell lysates were incubated with anti-ER␣ antibodies, and the presence of AP-1 proteins was analyzed by Western blot analysis (Fig. 5, A and B) . The results in Fig. 5, A and (Fig. 5, C and D) . Taken together, these results suggest that Cd promotes ER␣/c-Jun complex formation.
Having demonstrated that Cd can promote the ER␣/c-Jun interaction and that Cd promotes ER␣ recruitment to the promoters of target genes, we evaluated whether c-Jun is directly involved in ER␣-mediated transcription after Cd treatment. To address this question, we examined the recruitment of c-Jun to the promoter regions of CycD1 and c-myc using a second ChIP. The occupancy of c-Jun on the promoter regions of both cmyc and CycD1 is expected because both regions analyzed contain an AP-1 response element; however, the results presented in Fig. 6 , A and B, show that higher levels of c-Jun were recruited to the CycD1 and c-myc promoters in Cd-treated cells in comparison with untreated cells. In contrast, c-Jun occupancy was not observed at the U6 RNA promoter. To determine whether c-Jun and ER␣ are part of the same transcription complex, we performed a ChIP re-ChIP assay. MCF-7 cells were treated with 10 Ϫ6 M Cd, and cells were harvested for
ChIP analysis with the first antibody (either ER␣ or cJun). After the first ChIP assay, the DNA-protein complexes were extracted and re-ChIPed with the second antibody (either ER␣ or c-Jun). Our results confirm that Cd promotes the recruitment of both ER␣ and c-Jun to the same promoter region, suggesting that they are likely part of the same transcription complex (Fig. 6, C and D) .
To understand the role of c-Jun in Cd-induced gene expression, we analyzed the expressions of CycD1 and c-myc after siRNA-mediated silencing of c-Jun (Fig. 7,  A-C) . Expression analysis at the protein and mRNA lev- els confirmed that the expressions of CycD1 and c-myc are decreased in cells transfected with Ri-c-Jun. To further discern the role of c-Jun in Cd-induced cell growth, we transfected MCF-7 cells with either Ri-c-Jun or a control siRNA. Cells were treated with either Cd, E2, or mock treated with PBS (C), and growth was monitored 3 d after treatment (Fig. 7D) . Although the depletion of c-Jun diminishes the levels of agonist-induced cell growth and gene expression, cells continue to display some level of Cd and estrogen responsiveness. This may be attributed to the incomplete silencing of c-Jun by the siRNA. Taken together, results from this study strongly suggest Cd promotes the binding of ER␣ to c-Jun to regulate the expression of Cd-induced gene and promote breast cancer cell growth.
Discussion
Cd is an environmental contaminant that is often referred to as an endocrine disruptor due to its ability to mimic the ER and alter the expression of various estrogen target genes. Previous studies have suggested that exposure to Cd can affect mammary gland development in ovarectomized rats (2) . Although there is no direct evidence that Cd can promote breast cancer in humans, it has been implicated as a cancer causing agent and has been classified by the International Agency for Research on Cancer as a potential human carcinogen. Studies have demonstrated that Cd can promote growth of MCF-7 breast cancer cells and can activate the ER in vitro (1, 6 -8, 21, 22) . However, the mechanism of action of Cd is poorly understood. Results from this study confirm that Cd can promote cell proliferation in three human ER␣-positive breast cancer cell lines, MCF-7, T-47D, and ZR-75-1 (Fig. 1A) . Furthermore, our results demonstrate that Cd does not promote proliferation in ER␣-negative breast cancer cells (Supplemental Fig. 1) .
To fully establish a link between Cd-induced breast cancer cell growth and the ER, we used ICI and Ri-ER␣ to reduce the intracellular levels of ER␣. We found that both ICI and Ri-ER␣ were able to block Cd's action, suggesting that Cd-induced cell growth and gene expression are dependent on the ER (Fig. 2 and Supplemental Fig. 1 ). Consistent with previous reports, we found that multiple ER target genes (CycD1, c-myc, and CTD) are up-regulated by Cd exposure (Fig. 1, B and C) (1, 6, 7) . Additionally, our analysis demonstrates that cells exposed to Cd also expressed higher levels of CycE, cdk2, and cdk4 and decreased levels of p21. All of these genes function as cell cycle regulators that modulate progression of cells through the G 1 /S transition (Fig. 1, B and C) . Overexpression of any one of these cell cycle regulators Normal rabbit serum was used as a negative control. The occupancy of ER␣/c-Jun complexes on target promoters was analyzed using promoterspecific primers and semiquantitative RT-PCR. Band intensities of PCR products were quantitated using Quantity One (Bio-Rad).
results in the deregulation of growth, often leading to cancer (23) (24) (25) (26) .
Results from our reporter gene assay further support the argument that Cd stimulates the expression of CycD1 and c-myc by increasing the transcriptional activity of these target promoters. Because CycD1 and c-myc are both ER target genes, we fully expected to observe ER␣ occupancy at the CycD1 and c-myc promoters. Before this study, it was unclear whether Cd was responsible for stimulating the binding of ER␣ to these promoters or whether Cd induced nongenomic effects, leading to elevated levels of CycD1 and c-myc. Using ChIP analysis, we demonstrated that Cd enhances the recruitment of ER␣ to the proximal promoters of CycD1 and c-myc (Fig. 4) . This finding is further supported by the observation that Cd promotes the translocation of ER␣ into the nucleus, consistent with ER␣'s role as a transcriptional regulator (Fig. 3) .
Both CycD1 and c-myc are nonclassical ER target genes, and their expression, although dependent on ER␣, does not require direct binding of ER␣ to the DNA. Instead, ER␣ is recruited to their promoters via AP-1 (27, 28) . AP-1 is a transcription factor complex that contains proteins encoded by the proto-oncogenes c-Jun, c-Fos, and other AP-1 family members. This complex interacts with AP-1 binding sites in promoters to activate transcription of genes involved in cell growth, differentiation, and development. Previous studies have shown that c-Fos and c-Jun suppress ER␣-dependent trans-activation of estrogen response element-containing promoters (29 -31) by recruiting ER␣ to AP-1 promoters. ER␣ has been shown to cross talk with AP-1 and coregulate genes like CycD1 and c-myc (28, 32) . Here, we have demonstrated for the first time that Cd exposure increases the interaction between ER␣ and c-Jun, but not between ER␣ and c-Fos (Fig. 5) . These data are in accordance with the recent finding that stress induced by arsenic exposure increases ER␣-bound c-Jun (33) . Like Cd, arsenic is a heavy metal and the ER␣/c-Jun interaction has been shown to neutralize heavy metal stress to avoid apoptosis (33) . In the case of Cd, this interaction stimulates the expression of genes to mediate breast cancer cell growth. Our findings demonstrate that Cd enhances the recruitment of c-Jun to the CycD1 and c-myc promoters (Fig. 6, A and B) and that ER␣ is likely recruited to these promoters via its interaction with c-Jun (Fig. 6, C and D) . We extended our analysis using siRNA to deplete the endogenous levels of c-Jun and further demonstrated that c-Jun is necessary for the expression of Cd-induced CycD1 and c-myc expression. This is consistent with previous studies that have reported that Cd exposure increases the binding of c-Jun to the AP-1 site, and subsequently increases the trans-activation of AP-1 promoters (34 -36) . Together with this report, the data from our study suggest that Cd is involved in facilitating the cross talk between ER␣ and other transcription factors, such as c-Jun, to regulate expression of Cd-induced genes. In support of our findings, a recent study has also revealed that Cd activates the Erk1/2 and Akt kinases, resulting in the phosphorylation of ER␣, which has been shown to promote the ER␣/c-Jun interaction (22, (37) (38) (39) . We anticipate that Cd may function to mediate protein-protein interactions between ER␣ and other transcription factors, providing an alternative mechanism for activating Cdinduced gene expression. This possible mechanism would also explain the failure of recent studies to demonstrate Cd's estrogenic activity using a pure estrogen response element in a yeast estrogen screen (40, 41) .
In summary, the results from this study demonstrate for the first time that Cd promotes breast cancer cell growth and gene expression by potentiating the interaction between ER␣ and c-Jun and enhancing the binding of these transcription factors to target gene promoters. We speculate that Cd mediates ER␣ cross talk with other transcription factors, including Sp1, E2F, and NFB family members, to regulate additional Cd-induced genes. It would be very interesting to investigate a possible transcription factor complex or complexes involved in regulating the expression of CycE, cdk2, and other non-ER target genes that are up-regulated in response to Cd treatment (Fig. 1, B and C) . The role of ER␤ in Cd-mediated growth and gene expression appears to be minimal because siRNA-mediated depletion of ER␤ did not alter the Cd responsiveness of the cells (Fig. 2, E and F) . The results presented in this study have established a direct link between Cd-induced ER␣-regulated gene expression and breast cancer, and underscore the importance of Cd exposure in breast carcinogenesis.
Materials and Methods

Cell culture
Human MCF-7, T-47D, ZR-75-1, and MDA-MB-453 breast cancer cells were obtained from the American Type Culture Collection (Manassas, VA). All cells, except T-47D, were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and antibiotics. T-47D cells were maintained in RPMI 1640 supplemented with 10% FBS, sodium pyruvate, and antibiotics. All cell lines were subcultured every 3-4 d.
Cell proliferation analysis
Cells were plated at a density of 2 ϫ 10 5 per well in a six-well plate and hormone deprived for 2 d. Hormone deprivation is performed by maintaining cells in media containing 10% charcoal-dextran stripped FBS (CDS). Cells were treated with 10 
Western blot analysis
MCF-7 cells were plated and treated as described above and harvested 24 and 48 h after treatment. Cells were lysed in 1% sodium dodecyl sulfate-HEPES buffer, and the total protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad). Total protein was separated via SDS-PAGE and transferred to a poly(vinylidene difluoride) membrane. Protein expression was monitored using protein-specific antibodies: ␣-ER (BD, Franklin Lakes, NJ), ␣-ER␤, ␣-CycE, ␣-cdk2, ␣-p21, ␣-E2F1, ␣-c-Jun (Santa Cruz Biotechnology, Inc.), ␣-CycD1 (Transduction Laboratories, Lexington, KY), and ␣-actin (Sigma). 
RT-PCR analysis
MCF-7 cells were plated and treated as previously described. Cells were harvested for mRNA analysis 24 and 48 h after treatment. Total RNA was isolated using the Trizol reagent according to the manufacturer's protocol. Three micrograms of total RNA, Moloney murine leukemia virus RT (Invitrogen, Carlsbad, CA), and oligo-dT 18 primers were used in the RT reaction. Gene expression was monitored using 3 l of cDNA and gene-specific primers by 28 cycles of semiquantitative PCR (Bio-Rad). PCR products were analyzed by agarose gel electrophoresis, and bands were visualized with a ChemiDoc Imager (Bio-Rad the presence of SYBR Green fluorophore (Superarray, Frederick, MD) and detected using the iCycler real-time PCR equipment (Bio-Rad). Fluorescent values after each elongation step were collected along with a melting curve analysis at the end of the PCR. Fold difference (N) was calculated using the equation: n ϭ E (CT-treated Ϫ CT control) between treated cells and mock-treated (control) cells. E is defined as the PCR efficiency of the specific primer pair used and was determined by the standard curve [E ϭ10
(1/slope of standard curve) ]. CT is the threshold cycle, which is defined as the minimum cycle number at which the fluorescence of the PCR product is first detected.
Reporter gene assay
The reporter gene assay with promoter-luc was performed by transfecting MCF-7 cells with the firefly luciferase reporter plasmid, pBV-myc promoter (2.1 kb) or pA3-CycD1 promoter (1.7 kb), and with the pRL-SV40 Renilla luciferase plasmid (Promega) using Lipofectamine (Invitrogen) according to the manufacturer's protocol. Five hours after transfection, the medium was changed to hormone-deprived media containing 10 Ϫ6 M CdCl 2 , 10 Ϫ7 M 17␤-E 2 , or 1ϫ PBS. Cells were harvested at 48 h after transfection and analyzed using a dual luciferase assay kit (Promega). All reporter gene assays were performed in triplicate, with the entire experiment repeated at least three times. pBVmyc (2.1 kb) was obtained from Addgene and the pA3-CycD1 promoter (1.7 kb) was a kind gift of Dr. Richard Pestell (9) .
For the RNAi silencing experiments, MCF-7 cells were seeded in 24-well plates and transfected firefly luciferase reporter plasmid, pBV-myc promoter (2.1 kb) or pA3-CycD1 promoter (1.7 kb), and with the pRL-SV40 Renilla luciferase plasmid (Promega, Madison, WI) in the presence of either ER␣, c-Jun, ER␤, or control siRNA using siRNA transfection reagent (Santa Cruz Biotechnology, Inc.). Five hours after transfection, the medium was changed to hormone deprived, and 24 h later, cells were treated with 10 Ϫ6 M CdCl 2 , 10 Ϫ7 M 17␣-E 2 , or mock treated with PBS. Cells were harvested at 48 h after treatment and analyzed using a dual luciferase assay kit (Promega).
ChIP
MCF-7 cells were plated in 10-cm plates and hormone deprived for 1.5 d. Cells were treated with 10 Ϫ6 M CdCl 2 for 30 h. After treatment, the cells were fixed with formaldehyde, scraped, and collected by centrifugation. ChIP was performed as previously described (10) . Briefly, equal numbers of cells were lysed and sonicated in lysis buffer to break the chromatin down to 1-to 2-kb fragments. The chromatin mixture was immunoprecipitated with antibodies specific for the proteins of interest [1:1 mixture of ␣-ER antibodies: HC-20 and MC-20 or ␣-c-Jun (Santa Cruz Biotechnology, Inc.)]. Antibody complexes were purified using either protein A or G beads. The complexes were reverse-cross-linked to release the chromatin fragments, and the DNA was purified using QiaQuick columns (QIAGEN, Valencia, CA). Occupancy at a specific promoter was detected by PCR using the promoter-specific primers listed below. PCR products ranging 300 -500 bp were separated by agarose gel electrophoresis and visualized using the ChemiDoc system (Bio-Rad). The sequences of the ChIP primers are listed below: CycD1-ChIP F , CATTCAGAGGTGTGTTTCTCCC CycD1-ChIP R , CTCAGCGACTGCATCTTCTTTC c-myc-ChIP F , GACACATCTCAGGGCTAAACAG c-myc-ChIP R , GAGAGTGGAGGAAAGAAGGGTA U6RNA-ChIP F , GAGGGCCTATTTCCCATGATTC U6RNA-ChIP R , GAATTTGCGTGTCATCCTTGC
ChIP re-ChIP
For the re-ChIP assay, protein A-antibody complexes resulting from the first ChIP were extracted twice by incubation with 25 l of 10 mM dithiothreitol for 20 min each at 37 C. The supernatants were pooled and diluted 10 times with re-ChIP buffer (20 mM Tris⅐HCl, pH 8.1; 2 mM EDTA; 150 mM NaCl; and 0.1% Triton X-100). The chromatin mixture was reChIPed with the second antibody: ␣-ER (1:1 mixture of ␣-ER antibodies: HC-20:MC-20), ␣-c-Jun, or normal rabbit IgG, (Santa Cruz Biotechnology, Inc.). Antibody complexes were purified using protein A beads. The complexes were reverse-crosslinked to release the chromatin fragments by incubation at 65 C for 4 -6 h, and the DNA was purified and analyzed as previously described.
